Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

BeOne Medicines is investing another $300 million in its Princeton West Innovation Campus in Hopewell, New Jersey, taking its total investment in the site beyond $1 billion. The expansion will add a three-storey, 145,000-square-foot building for small-molecule drug product manufacturing,
An FDA advisory committee has narrowly supported adding BPC-157, KPV, TB-500, and MOTS-c-related substances to the list of bulk ingredients that may be used by eligible 503A compounding pharmacies. The decision could reshape access to peptides already promoted across wellness
Amgen has submitted a new evidence package to defend Tavneos and request an FDA hearing. However, the dispute no longer focuses only on whether the drug can help patients with ANCA-associated vasculitis. The regulator now questions whether the pivotal ADVOCATE
The FDA has expanded artificial intelligence across regulatory reviews, inspections, and administrative work. However, the departure of former commissioner Dr. Marty Makary and other senior technology leaders has created uncertainty around the agency’s AI strategy. Although the FDA continues to
Ashlins Pharmaceuticals has licensed ex-China rights to develop products using Lee’s Pharm’s interferon alpha-2b API in a deal worth up to $31 million. The rare disease startup now plans to raise about $50 million and believes the funding could take
The FDA reportedly plans to appoint permanent leaders for CDER and CBER when the White House names its next commissioner nominee. This FDA leadership reset aims to stabilize two centers that shape major drug and biologics decisions. However, pharmaceutical companies
Verseon has challenged one of pharma’s strongest AI drug discovery promises: that data-driven models can consistently create truly novel medicines. In a July 22, 2026 report, the Bay Area drug developer argued that most AI platforms remain tied to known
Novo Nordisk filed a federal lawsuit against Eli Lilly in New Jersey on July 21, 2026, accusing the company of misleading consumers through national advertising for Zepbound and Mounjaro. Novo claims Lilly compared its highest drug doses with lower doses
Karen Habercoss, chief information security and privacy officer at the University of Chicago Medicine, warned that hackers and nation-states now use AI to automate and scale cyberattacks. Her warning extends beyond hospitals. In pharma operations, the same technology supporting QA
Bristol Myers Squibb announced on July 20, 2026, that it will expand its artificial intelligence infrastructure through a new NVIDIA DGX SuperPOD equipped with Vera Rubin NVL72 systems. BMS plans to use the infrastructure across several research areas, including oncology,